NCT06412965Completed
Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine
Evaluation of the Reliability of Effect of Rimegepant for the Acute Treatment of Migraine Across Multiple Attacks
Source: ClinicalTrials.gov · Last updated 13 Jan 2025
Brief summary (registry, in English)
This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute treatment for migraine attacks.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 528 (actual)
- First submitted
- 16 Apr 2024
- Start date
- 2 Jan 2024
- Primary completion date
- 3 Jan 2024
- Lead sponsor
- Pfizer
- Diseases
- Migraine
- NCT number
- NCT06412965
What you commit to
- Study type: Observational
- Participants enrolled: 528
- From 2 Jan 2024 to the primary completion date, 3 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- currently prescribed rimegepant for prevention of migraine or for both the acute treatment \& prevention of migraine
- Rimegepant group: currently prescribed an acute treatment for migraine and other than rimegepant
- Triptan Group: currently prescribed an acute treatment for migraine other than triptans
Who the study is looking for
- Patients who have episodic and/or chronic migraine
- Patients age \> 18
- Currently prescribed rimegepant OR triptans for the acute treatment of migraine
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.